On Friday, the U.S.
Food and Drug Administration (FDA) approved Lantheus Holdings Inc.'s (NASDAQ:LNTH) Tauklarify (florquinitau F 18 injection).
Also known as MK-6240, this radiodiagnostic agent is designed for positron emission tomography (PET) scans of the brain in adult patients experiencing cognitive impairment who are undergoing evaluation for Alzheimer's disease.
The agent helps identify patients with tau neurofibrillary tangle (NFT) pathology.
The company noted a limitation of use, stating that Tauklarify's safety and effectiveness in evaluating non-Alzheimer's disease tauopathies have not been established.
